0QBO.LSE

Coloplast A/S

0QBO.LSE, UK

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

https://www.coloplast.com

Stock Price

DKK0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2022-12-31)

Health Score

Investors

* Institutions hold a combined 0.00% of the total shares of Coloplast A/S

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

6.49

Latest Release

Date

2025-09-30

EPS Actual

3.8826

EPS Estimate

7.05

EPS Difference

-3.1674

Surprise Percent

-44.9277%

Investing Fit Scorecard

(Last Updated 2022-12-31)

Deep Value
Weak Deep Value(0.5)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(1.5)
GARP
Not Attractive for GARP(0)
Growth
Weak Growth Prospect(0)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(0)
Quality
Low Quality Business(0.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2022-12-31)

Revenue

DKK 0

Cost Of Revenue

DKK 0

Gross Profit

DKK 0

Operating Expenses

DKK 0

Operating Income

DKK 0

Interest Expense

DKK 0

Pretax Income

DKK 0

Net Income

DKK 0

Income Tax Expense

DKK 0

EBITDA

DKK 0

Total Other Income Expense Net

DKK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2022-12-31)

Cash

DKK 0

Short Term Investments

DKK 0

Receivables

DKK 0

Inventories

DKK 0

Total Current Assets

DKK 0

Property Plant Equipment

DKK 0

Total Assets

DKK 0

Payables

DKK 0

Short Term Debt

DKK 0

Long Term Debt

DKK 0

Total Liabilities

DKK 0

Equity

DKK 0

Trend

Cash Flow

(Last Updated 2022-12-31)

Net Income

DKK 0

Depreciation

DKK 0

Change In Working Capital

DKK 0

Cash From Operations

DKK 0

Capital Expenditures

DKK 0

Cash From Investing

DKK 0

Cash From Financing

DKK 0

Net Change In Cash

DKK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.